Interleukin-17 and Interleukin-10 Association with Disease Progression in Schizophrenia

Raghavi Chenniappan¹, Hanumanthappa Nandeesha¹, Shivanand Kattimani², and Nandakumar Dalavaikodihalli Nanjaiah³

Abstract

Background: Alteration in cytokine levels are known to be involved in the pathogenesis of schizophrenia.

Objectives: To estimate the serum levels of interleukin-17 (IL-17) and interleukin-10 (IL-10) and their association with disease progression in schizophrenia.

Methods: A total of 67 schizophrenia cases were enrolled in the present study. IL-17 and IL-10 were estimated by enzyme-linked immunosorbent assay. Positive and Negative Syndrome Scale (PANSS) was used to evaluate disease severity.

Results: IL-17 was positively correlated with positive symptom score ($r = 0.256, p = 0.036$), general psychopathology score ($r = 0.255, p = 0.038$) and total score ($r = 0.273, p = 0.025$) in schizophrenia. IL-17 and IL-10 were significantly increased in schizophrenia cases with PANSS more than 85 compared to those with 71–85.

Conclusion: IL-17 and IL-10 are associated with disease severity in schizophrenia but are not good markers for predicting the disease progression.

Keywords

Schizophrenia, interleukins, inflammation, psychopathology, disease progress, cytokines

Abbreviations

IL-17: interleukin-17; IL-10: interleukin-10; PANSS: positive and negative syndrome scale

Introduction

The prevalence of schizophrenia is increasing worldwide, including India. According to recent National Mental Health Survey, its prevalence is around 0.5% in India.¹ While the etiology of schizophrenia is considered multifactorial, several studies support the alterations of inflammatory processes in its pathogenesis.² Interleukin-17 (IL-17), a Th17 cytokine increases the production of other proinflammatory cytokines like IL-6 and IL-8.³ IL-17 is involved in the pathogenesis of several neurological disorders.⁴ Autism spectrum disorder development was found to be associated with the dysregulation of IL-17A.⁵ The previous studies in schizophrenia have documented contradictory reports related to IL-17 levels. El Kissi et al have reported elevated IL-17 levels, whereas Dimitrov et al have reported reduced values of IL-17 in patients with schizophrenia when compared with controls and demonstrated that IL-17 was negatively associated with negative symptoms of schizophrenia.⁶,⁷

Interleukin-10 (IL-10) is considered as neuroprotective cytokine, which prevents neuronal dysfunction.⁸ Alzheimer’s disease and multiple sclerosis were found to be associated with the alteration in IL-10 levels.⁹,¹⁰ IL-10 based treatment modalities have been found to be useful in the treatment of neuroimmune diseases.¹¹ Xiu et al have demonstrated that reduced IL-10 levels in schizophrenia were related to cognitive impairment and negative symptoms.¹² Maes et al have reported an increase in IL-10 levels on treatment with

¹ Department of Biochemistry, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
² Department of Psychiatry, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India
³ Department of Neurochemistry, National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, Karnataka, India

Corresponding author:
Hanumanthappa Nandeesh, Department of Biochemistry, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry 605006, India.
E-mail: nandijipmer@gmail.com

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-Commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
neuroleptics. Dimitrov et al have suggested that IL-10 is associated positively with severity of schizophrenia.

Since an imbalance in pro- and anti-inflammatory cytokines plays a role in the development of schizophrenia, the objective of the study was to estimate IL-17 and IL-10 levels and their relation with disease progression in schizophrenia.

Materials and Methods

It is a case control study done in a tertiary care hospital in southern India. A total of 67 schizophrenia patients in the age group of 18–45 years were enrolled in the study. Schizophrenia was diagnosed according to Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) criteria. Those with medical/neurological comorbidities, previous substance use and those who are on treatment for any neurological or psychiatric disorders were excluded.

The study was approved by JIPMER Ethics Committee (Reg. no. JIP/IEC/2015/20/708, dated 30/10/2015). A written informed consent was obtained from all the subjects or their legally acceptable representatives. A 5 mL of blood sample was collected, and the serum obtained was used to estimate IL-17 and IL-10. Enzyme-linked immunosorbent assay (ELISA) technique (Diaclone kits, France) was used to estimate IL-17 and IL-10. Positive and Negative Syndrome Scale (PANSS) was used to evaluate severity of schizophrenia.

Statistical Analysis

One-way ANOVA was used to compare the clinical characteristics and interleukins among subgroups of schizophrenia based on PANSS score. Pearson’s correlation analysis was used to investigate the relation between interleukins and PANSS scores. Receiver operating characteristic (ROC) curve analysis was performed to identify the cutoff value, specificity and sensitivity of IL-17 and IL-10 in schizophrenia cases with increase in PANSS score. All the statistical tests were considered significant if the p value was less than .05.

Results

The clinical characteristics and interleukins are shown in Table 1. The mean duration of illness in schizophrenia was 18 months (range: 1–240 months). A total of 41 patients were drug naive and 26 were drug defaulters. The median (ranges) value for IL-10 was 8.58 (0.34–65.19) and for IL-17 was 7.20 (5.60–39). The mean positive symptoms score was 23, negative symptom score was 17 and total symptom score was 79. Among drug naive and drug defaulters, the difference in PANSS scores, IL-17 and IL-10 was not significant (data not shown).

Table 2 shows the correlations of interleukins with PANSS scores. IL-17 was significantly associated with positive symptom score ($r = 0.256, p = .036$), general psychopathology score ($r = 0.255, p = .038$) and total score ($r = 0.273, p = .025$) in schizophrenia. We did not find any significant correlation of IL-10 with IL-17 and PANSS score.

Table 3 shows age, duration of illness, and biochemical parameters in schizophrenia cases with increase in PANSS score. IL-17 and IL-10 were significantly increased in schizophrenia cases with PANSS more than 85 compared to those with 71–85.

| Parameters | Schizophrenia (n = 67) |
|------------|------------------------|
| Age (years) | 31.90 ± 9.35            |
| Gender (M/F) | 30/37                  |
| Drug naive/drug defaulters | 41/26          |
| Duration of illness (months) | 18 (1–240) |
| Interleukin-10 (µg/L) | 8.58 (0.34–65.19) |
| Interleukin-17 (µg/L) | 7.20 (5.60–39) |
| Positive symptom score | 23.24 ± 5.46 |
| Negative symptom score | 17.27 ± 5.81 |
| General psychopathology symptom score | 38.49 ± 6.71 |
| Total symptom score | 79 ± 14.35 |

Table 1. General Characteristics, Duration of Illness, Interleukins, and PANSS Scores in Schizophrenia (n = 67)

| Parameters | Interleukin-17 r | Interleukin-10 r |
|------------|----------------|----------------|
| Age        | 0.194          | -0.015         |
| Duration of illness | 0.016  | -0.037         |
| Positive symptoms | 0.256  | 0.097          |
| Negative symptoms | 0.139  | 0.200          |
| General psychopathology symptom score | 0.255  | 0.200 |
| Total symptom score | 0.273  | 0.175          |
| Interleukin-10 | 0.009  | .941 |

Table 2. Correlation of IL-17 and IL-10 with PANSS Score in Schizophrenia (n = 67)

| Parameters | Group A (n = 22) | Group B (n = 24) | Group C (n = 21) |
|------------|----------------|----------------|----------------|
| Total Score | 35.5–70 | Total Score | 71–85 | Total Score | >85 |
| Age        | 34.55 ± 11.56 | 31.04 ± 9.27 | 30.10 ± 6.14 |
| Gender (M/F) | 7/15 | 12/12 | 11/10 |
| Drug naive/drug defaulters | 14/8 | 15/9 | 12/9 |
| Duration of illness (months) | 16 (1–240) | 12 (1–132) | 24 (1–144) |
| Interleukin-10(µg/L) | 12.89 | 6.79 | 8.49 |
| Interleukin-17(µg/L) | 8.4 ± 2.52 | 6.8 ± 0.9 | 9.5 ± 7.3 |

Note: *p < .05 compared to Group B (those with total score of 85–71).
ROC curve analysis revealed IL-17 can predict the progression of schizophrenia at cutoff level of 6.95, specificity—54%, sensitivity—52% (Figure 1). At cutoff level of 7.59 µg/L, we found that IL-10 can predict the progression of schizophrenia with 57% sensitivity and 58% specificity (Figure 2).

**Discussion**

Dysfunction of immune system is considered to increase the progression of schizophrenia. Schizophrenia is linked with chronic low-grade inflammation, and several investigators have demonstrated aberrant cytokine levels in these patients. The present study is the first study to investigate IL-17 and IL-10 levels and its association with progression of schizophrenia in Indian population.

Interleukin 17A is a pro-inflammatory cytokine, produced by T helper 17 cells (lymphocyte). The reports about IL-17 levels are inconsistent with investigators demonstrating either elevated or reduced values in schizophrenia. The effect of antipsychotics on IL-17 levels has been investigated by earlier studies. Ding et al have reported decreased IL-17 levels, and Himmerich et al have demonstrated elevated IL-17 levels after treatment with antipsychotics in patients with schizophrenia. In the present study, there was a significant association of IL-17 with positive score ($p = .036$), general psychopathology score ($p = .038$), and total score ($p = .025$). Till date in literature, there is paucity of data about IL-17 levels with increase in PANSS score in schizophrenia patients. In the present study, IL-17 levels were significantly increased in patients with PANSS score more than 85 compared to those with lesser score. ROC curve analysis revealed IL-17 can predict the progression of schizophrenia at cutoff level of 6.95, specificity—54%, sensitivity—52%. It has been proposed by previous investigators that altered state of neurotransmitters like dopamine and γ-aminobutyric acid (GABA) can stimulate secretion of proinflammatory cytokines like IL-17, which in turn causes structural and functional neuronal changes in schizophrenia.

Several evidences have supported the involvement of IL-10 in schizophrenia. Earlier researchers have shown reduction in blood IL-10 levels in schizophrenia patients with relapse of symptoms. Subjects with lower IL-10 production genotypes were reported to be at increased risk of developing schizophrenia suggesting that low anti-inflammatory cytokines increase inflammation, which in turn increases the risk of schizophrenia. In the present study, IL-10 was not associated with PANSS score significantly. In contrast, a previous study has documented an association of IL-10 with symptoms of schizophrenia. Among different schizophrenia subgroups, we observed that IL-10 levels were more in patients with PANSS score more than 85 compared to those with score of 71–85. At cutoff level of 7.59 µg/L, we found that IL-10 can predict the progression of schizophrenia with 57% sensitivity and 58% specificity.

The main limitation of this study was noninclusion of control group due to financial and ethical constraints. Also, we did not analyze other proinflammatory cytokines due to financial constraints. ELISA was performed on the stored sample as it can be done only when adequate samples are collected, and inadequate technical resources do not allow fresh samples to be analyzed.
Conclusion

IL-17 and IL-10 are associated with disease severity in schizophrenia, but they cannot be used as predictive biomarkers of disease progression in schizophrenia. Future research works are needed to investigate the central nervous system source and mechanism of IL-17 and IL-10 release specifically during schizophrenia. Further studies are needed to evaluate the effect of anti-inflammatory agents on IL-17 levels and progression of schizophrenia.

Acknowledgments

This work was supported by an intramural grant from JIPMER, Puducherry to the corresponding author. Technical assistance of Mrs. Durgadevi, laboratory technician, is greatly appreciated.

Author Contributions

RC: Data acquisition and analysis
HN: Concept and design of the study, statistical analysis, manuscript preparation
SK: Design of the study, data acquisition, manuscript editing and review
NDN: Analysis, manuscript editing and review

Ethical Statement

The study protocol was approved by the JIPMER ethics committee and informed consent was obtained from all the subjects and or their wards.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Institute (JIPMER) intramural fund.

References

1. Srinivasa Murthy R. National Mental Health Survey of India 2015–2016. Indian J Psychiatry 2017; 59(1): 21–26.
2. Pedrini M, Massuda R, Fries GR, et al. Similarities in serum oxidative stress markers and inflammatory cytokines in patients with overt schizophrenia at early and late stages of chronicity. J Psychiatr Res 2012; 46 (6): 819–824.
3. Miossec P. Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice. RMD Open 2017; 3(1): e000284.
4. Tahmasebinia F and Pourgholaminejad A. The role of Th17 cells in auto-inflammatory neurological disorders. Prog Neuropsychopharmacol Biol Psychiatry 2017; 79: 408–416.
5. Wong H and Hoeffer C. Maternal IL-17A in autism. Exp Neurol 2018; 299: 228–240.
6. El Kissi Y, Samoud S, Miraoui A, et al. Increased interleukin-17 and decreased BAFF serum levels in drug free acute schizophrenia. Psychiatry Res 2015; 225(1–2): 58–63.
7. Dimitrov DH, Lee S, Yantis J, et al. Differential correlations between inflammatory cytokines and psychopathology in veterans with schizophrenia: potential role for IL-17 pathway. Schizophr Res 2013; 151(1–3): 29–35.
8. Lobo-Silva D, Carriche GM, Castro AG, et al. Balancing the immune response in the brain: IL-10 and its regulation. J Neuroinflammation 2016; 13(1): 297.
9. Magalhães CA, Carvalho MDG, Sousa LP, et al. Alzheimer’s disease and cytokine IL-10 gene polymorphisms: is there an association? Arq Neuropsiquiatr 2017; 75(9): 649–656.
10. Ramakrishnan V, Akram Husain RS, Ahmed SS. Genetic predisposition of IL-10 promoter polymorphisms with risk of multiple sclerosis: a meta-analysis. J Neuroimmunol 2017; 306: 11–18.
11. Kwilasz AJ, Grace PM, Serbedzija P, et al. The therapeutic potential of interleukin-10 in neuroimmune diseases. Neuropharmacology 2015; 96: 55–69.
12. Xiu MH, Yang GG, Tan YL, et al. Decreased interleukin-10 serum levels in first-episode drug-naïve schizophrenia: relationship to psychopathology. Schizophr Res 2014; 156(1): 9–14.
13. Maes M, Bocchio Chiavetto L, Bignotti S, et al. Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr Res 2002; 54(3): 281–291.
14. Kay SR, Fiszbein A, and Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13(2): 261–276.
15. Debnath M and Berk M. Functional implications of the IL-23/IL-17 immune axis in schizophrenia. Mol Neurobiol 2017; 54(10): 8170–8178.
16. Ding M, Song X, Zhao J, et al. Activation of Th17 cells in drug naïve, first episode schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2014; 51: 78–82.
17. Himmerich H, Schönherr J, Fulda S, et al. Impact of antipsychotics on cytokine production in-vitro. J Psychiatr Res 2011; 45: 1358–1365.
18. Upthegrove R and Barnes NM. The immune system and schizophrenia: an update for clinicians. Adv Psychiatr Treat 2014; 20: 83–91.
19. Smith RS and Maes M. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med Hypotheses 1995; 45: 135–141.
20. Miller BJ, Buckley P, Seabolt W, et al. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011; 70: 663–671.

21. Gao L, Li Z, Chang S, et al. Association of interleukin-10 polymorphisms with schizophrenia: a meta-analysis. PLoS One 2014; 9(3): e90407.

22. Şimşek Ş, Yıldırım V, Çim A, et al. Serum IL-4 and IL-10 levels correlate with the symptoms of the drug-naive adolescents with first episode, early onset schizophrenia. J Child Adolesc Psychopharmacol 2016; 26(8): 721–726.